Organogenesis Hldgs Analyst Ratings
Organogenesis Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 9.09% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 08/10/2023 | 45.45% | BTIG | $10 → $4 | Maintains | Buy |
| 06/15/2023 | 81.82% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 05/24/2023 | 263.64% | BTIG | → $10 | Upgrades | Neutral → Buy |
| 11/10/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 11/10/2021 | 627.27% | SVB Leerink | $26 → $20 | Maintains | Outperform |
| 08/10/2021 | 809.09% | Credit Suisse | $24 → $25 | Maintains | Outperform |
| 05/11/2021 | 845.45% | SVB Leerink | $27 → $26 | Maintains | Outperform |
| 03/17/2021 | 700% | SVB Leerink | $19 → $22 | Maintains | Outperform |
| 01/20/2021 | 372.73% | SVB Leerink | $10 → $13 | Maintains | Outperform |
| 01/07/2021 | 227.27% | Credit Suisse | $8 → $9 | Maintains | Outperform |
| 11/18/2020 | 263.64% | SVB Leerink | $9 → $10 | Maintains | Outperform |
| 11/10/2020 | 190.91% | Credit Suisse | $7 → $8 | Maintains | Outperform |
| 08/11/2020 | 227.27% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 05/12/2020 | 154.55% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 04/09/2020 | 190.91% | BTIG | $9 → $8 | Maintains | Buy |
| 01/10/2020 | 227.27% | SVB Leerink | → $9 | Initiates Coverage On | → Outperform |
| 08/26/2019 | — | Credit Suisse | Reinstates | → Outperform | |
| 05/02/2019 | 227.27% | Credit Suisse | → $9 | Initiates Coverage On | → Outperform |
| 04/17/2019 | 300% | Oppenheimer | → $11 | Initiates Coverage On | → Outperform |
| 04/12/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 04/11/2019 | 300% | SunTrust Robinson Humphrey | → $11 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月11日 | 9.09% | 摩根士丹利 | $5→$3 | 維護 | 等重 |
| 2023年08月10日 | 45.45% | BTIG | $10→$4 | 維護 | 買 |
| 2023/06/15 | 81.82% | 摩根士丹利 | →$5 | 開始承保 | →等重 |
| 2023年05月24日 | 263.64% | BTIG | →$10 | 升級 | 中性→購買 |
| 2022年11月10日 | - | BTIG | 評級下調 | 購買→中性 | |
| 2021年11月10日 | 627.27% | SVB Leerink | $26→$20 | 維護 | 跑贏大盤 |
| 2021/08/10 | 809.09% | 瑞士信貸 | $24→$25 | 維護 | 跑贏大盤 |
| 2021/11/05 | 845.45% | SVB Leerink | $27→$26 | 維護 | 跑贏大盤 |
| 03/17/2021 | 700% | SVB Leerink | $19→$22 | 維護 | 跑贏大盤 |
| 01/20/2021 | 372.73% | SVB Leerink | $10→$13 | 維護 | 跑贏大盤 |
| 01/07/2021 | 227.27% | 瑞士信貸 | $8→$9 | 維護 | 跑贏大盤 |
| 11/18/2020 | 263.64% | SVB Leerink | $9→$10 | 維護 | 跑贏大盤 |
| 11/10/2020 | 190.91% | 瑞士信貸 | $7→$8 | 維護 | 跑贏大盤 |
| 2020年08月11日 | 227.27% | SVB Leerink | $7→$9 | 維護 | 跑贏大盤 |
| 2020/05/12 | 154.55% | SVB Leerink | $8→$7 | 維護 | 跑贏大盤 |
| 04/09/2020 | 190.91% | BTIG | $9→$8 | 維護 | 買 |
| 2020/10/01 | 227.27% | SVB Leerink | →$9 | 開始承保 | →跑贏大盤 |
| 2019年08月26日 | - | 瑞士信貸 | 恢復 | →跑贏大盤 | |
| 2019年05月02日 | 227.27% | 瑞士信貸 | →$9 | 開始承保 | →跑贏大盤 |
| 2019/04/17 | 百分之三百 | 奧本海默 | →$11 | 開始承保 | →跑贏大盤 |
| 2019年4月12日 | - | BTIG | 開始承保 | →購買 | |
| 2019年4月11日 | 百分之三百 | SunTrust Robinson Humphrey | →$11 | 開始承保 | →購買 |
What is the target price for Organogenesis Hldgs (ORGO)?
有機生成Hldgs(Orgo)的目標價格是多少？
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by Morgan Stanley on August 11, 2023. The analyst firm set a price target for $3.00 expecting ORGO to rise to within 12 months (a possible 9.09% upside). 5 analyst firms have reported ratings in the last year.
有機生成Hldgs(納斯達克代碼：ORGO)的最新目標價是由摩根士丹利在2023年8月11日報道的。這家分析公司將目標價定為3.00美元，預計Orgo將在12個月內上漲至9.09%(可能上漲9.09%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Organogenesis Hldgs (ORGO)?
有機生成Hldgs(Orgo)的最新分析師評級是多少？
The latest analyst rating for Organogenesis Hldgs (NASDAQ: ORGO) was provided by Morgan Stanley, and Organogenesis Hldgs maintained their equal-weight rating.
有機生成類Hldgs(納斯達克代碼：ORGO)的最新分析師評級由摩根士丹利提供，有機生成類Hldgs維持同等權重評級。
When is the next analyst rating going to be posted or updated for Organogenesis Hldgs (ORGO)?
器官生成Hldgs(Orgo)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organogenesis Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organogenesis Hldgs was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與有機生成Hldgs的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。器官發生Hldgs的上一次評級是在2023年8月11日提交的，所以你應該預計下一次評級將在2024年8月11日左右提供。
Is the Analyst Rating Organogenesis Hldgs (ORGO) correct?
分析師對有機生成Hldgs(Orgo)的評級正確嗎？
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a maintained with a price target of $5.00 to $3.00. The current price Organogenesis Hldgs (ORGO) is trading at is $2.75, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的有機生成Hldgs(Orgo)評級保持不變，目標價在5.00美元至3.00美元之間。ORGO目前的交易價格為2.75美元，超出了分析師的預測區間。